| 内容提要: |
Application of low dosage of IL-2 has been demonstrated in many autoimmune disease treatments (Table.1). Patients with Systemic lupus erythematosus (SLE) were administered recombinant human IL-2 at a dose of 1 million IU for 3 cycles, once every two days for 2 weeks. Patients with Type 1 diabetes (T1D) were administered IL-2 3 MIU/day for a 5-day course, and followed up for 60 days. Other disease like Chronic graft-versus-host disease (GVHD), Hepatitis C virus-related autoimmunity, Alopecia Areata (AA) and immune thrombocytopenia (ITP) can be treated by low-dosage IL-2 in clinical trials [1]. |